Picture of Oncolytics Biotech logo

ONCY — Oncolytics Biotech News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousMicro CapSucker Stock

Brief: Oncolytics Says Pelareorep Shows Durable Survival Benefit in Anal Cancer

BRIEF-Oncolytics Says Pelareorep Shows Durable Survival Benefit in Anal Cancer

- Oncolytics Biotech Inc ONCY.O:

  • ONCOLYTICS BIOTECH® REPORTS STRONG DURABILITY AND SURVIVAL DATA IN ANAL CANCER, POSITIONING PELAREOREP AS POTENTIAL BACKBONE IMMUNOTHERAPY ACROSS HPV-DRIVEN CANCERS

Source text: ID:nGNX3lCKL3

Further company coverage: ONCY.O


(Reporting by Zakia Mariyam)

((Zakia.Mariyam@thomsonreuters.com;))

Recent news on Oncolytics Biotech

See all news